FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735080693> ?p ?o ?g. }

• W2735080693 endingPage "1061" @default.
• W2735080693 startingPage "1053" @default.
• W2735080693 abstract "Background The management of latent Mycobacterium tuberculosis infection is a new priority action for the WHO End Tuberculosis (TB) Strategy. However, national guidelines on latent tuberculosis infection testing and treatment have not yet been developed in China. Here, we present the results from the 2-year follow-up of a study that aimed to track the development of active disease in individuals with latent tuberculosis infection, identify priority populations for latent infection management, and explore the most suitable latent infection diagnostic approach. Methods A population-based multicentre prospective study was done in four sites in rural China, between 2013 and 2015. The baseline survey in 2013 measured the prevalence of latent tuberculosis infection using QuantiFERON-TB Gold In-Tube (QFT) and tuberculin skin test (TST) in eligible participants. During the follow-up phase between 2014–15, we assessed individuals who had tuberculosis infection at baseline (QFT-positivity or TST tuberculin reaction size [induration] of ≥10 mm) for the development of active disease through active case finding. Eligible participants included in follow-up survey had a birth date before June 1, 2008 (5 years or older in 2013), and continuous residence at the study site for 6 months or longer in the past year. Participants with current active tuberculosis at baseline survey were excluded. Findings Between Sept 1, 2013, and Aug 31, 2015, 7505 eligible participants (aged 5 years or older) were included in tuberculosis infection test positive cohorts (4455 were QFT positive, 6404 had TST induration ≥10 mm, and 3354 were positive for both tests) after baseline examination. During the 2-year follow-up period, 84 incident cases of active tuberculosis were diagnosed. Of participants who developed active tuberculosis, 75 were diagnosed with latent infection by QFT, 62 were diagnosed by TST, and 53 were diagnosed by both tests. An incidence rate of 0·87 (95% CI 0·68–1·07) per 100 person-years was observed for individuals who tested positive with QFT, 0·50 (0·38–0·63) per 100 person-years for those who tested positive with TST (p<0·0001), and 0·82 (0·60–1·04) per 100 person-years for those who tested positive with both tests. Male sex and a history of tuberculosis were significantly associated with increased risk of disease development with adjusted hazard ratios of 2·36 (95% CI 1·30–4·30) for male sex and 5·40 (3·34–8·71) for a history of tuberculosis. Interpretation Our results suggest that high-risk populations in communities in rural China, such as individuals at a high risk of disease reactivation from previous tuberculosis, should be targeted for latent infection screening and treatment with an interferon-γ releasing assay rather than a TST. Funding National Science and Technology Major Project of China, Program for Changjiang Scholars and Innovative Research Team in University of China, CAMS Innovation Fund for Medical Sciences, and Sanming Project of Medicine in Shenzhen." @default.
• W2735080693 created "2017-07-21" @default.
• W2735080693 creator A5000044349 @default.
• W2735080693 creator A5000207050 @default.
• W2735080693 creator A5000909048 @default.
• W2735080693 creator A5000919137 @default.
• W2735080693 creator A5001287866 @default.
• W2735080693 creator A5001536412 @default.
• W2735080693 creator A5001612078 @default.
• W2735080693 creator A5001921583 @default.
• W2735080693 creator A5002283504 @default.
• W2735080693 creator A5003166126 @default.
• W2735080693 creator A5003759585 @default.
• W2735080693 creator A5004188121 @default.
• W2735080693 creator A5004377841 @default.
• W2735080693 creator A5004381591 @default.
• W2735080693 creator A5005053576 @default.
• W2735080693 creator A5005280344 @default.
• W2735080693 creator A5005755463 @default.
• W2735080693 creator A5005912920 @default.
• W2735080693 creator A5006905226 @default.
• W2735080693 creator A5007257906 @default.
• W2735080693 creator A5007771003 @default.
• W2735080693 creator A5008096141 @default.
• W2735080693 creator A5008205192 @default.
• W2735080693 creator A5008387848 @default.
• W2735080693 creator A5008458949 @default.
• W2735080693 creator A5008482006 @default.
• W2735080693 creator A5008796127 @default.
• W2735080693 creator A5009060651 @default.
• W2735080693 creator A5009562280 @default.
• W2735080693 creator A5010444377 @default.
• W2735080693 creator A5010528351 @default.
• W2735080693 creator A5010576526 @default.
• W2735080693 creator A5010581622 @default.
• W2735080693 creator A5011150784 @default.
• W2735080693 creator A5011589105 @default.
• W2735080693 creator A5012063967 @default.
• W2735080693 creator A5012136645 @default.
• W2735080693 creator A5012501330 @default.
• W2735080693 creator A5012677271 @default.
• W2735080693 creator A5013235046 @default.
• W2735080693 creator A5014332718 @default.
• W2735080693 creator A5014401588 @default.
• W2735080693 creator A5014914917 @default.
• W2735080693 creator A5014929343 @default.
• W2735080693 creator A5015235929 @default.
• W2735080693 creator A5015572160 @default.
• W2735080693 creator A5015669107 @default.
• W2735080693 creator A5015763964 @default.
• W2735080693 creator A5015768742 @default.
• W2735080693 creator A5015979860 @default.
• W2735080693 creator A5016619673 @default.
• W2735080693 creator A5016852781 @default.
• W2735080693 creator A5017356220 @default.
• W2735080693 creator A5017557616 @default.
• W2735080693 creator A5017619322 @default.
• W2735080693 creator A5018488961 @default.
• W2735080693 creator A5018551141 @default.
• W2735080693 creator A5018724340 @default.
• W2735080693 creator A5018898066 @default.
• W2735080693 creator A5019856455 @default.
• W2735080693 creator A5019991864 @default.
• W2735080693 creator A5020037150 @default.
• W2735080693 creator A5020051753 @default.
• W2735080693 creator A5020150519 @default.
• W2735080693 creator A5020667128 @default.
• W2735080693 creator A5020731733 @default.
• W2735080693 creator A5021201269 @default.
• W2735080693 creator A5021235390 @default.
• W2735080693 creator A5021300873 @default.
• W2735080693 creator A5021338975 @default.
• W2735080693 creator A5022355218 @default.
• W2735080693 creator A5023450787 @default.
• W2735080693 creator A5023502696 @default.
• W2735080693 creator A5023537040 @default.
• W2735080693 creator A5023601895 @default.
• W2735080693 creator A5023801499 @default.
• W2735080693 creator A5023874610 @default.
• W2735080693 creator A5023936479 @default.
• W2735080693 creator A5024199853 @default.
• W2735080693 creator A5024899130 @default.
• W2735080693 creator A5025956560 @default.
• W2735080693 creator A5026381482 @default.
• W2735080693 creator A5026660665 @default.
• W2735080693 creator A5026865722 @default.
• W2735080693 creator A5026971765 @default.
• W2735080693 creator A5027654063 @default.
• W2735080693 creator A5027978435 @default.
• W2735080693 creator A5027999409 @default.
• W2735080693 creator A5028203797 @default.
• W2735080693 creator A5028938025 @default.
• W2735080693 creator A5029284270 @default.
• W2735080693 creator A5029802565 @default.
• W2735080693 creator A5029839025 @default.
• W2735080693 creator A5030135007 @default.
• W2735080693 creator A5030189213 @default.
• W2735080693 creator A5030222062 @default.

• next